Do, D V
,
Sepah, Y J
Boyer, D
Callanan, D
Gallemore, R
Bennett, M
Marcus, D M
Halperin, L http://orcid.org/0000-0002-7959-2306
Sadiq, M A
Rajagopalan, N
Campochiaro, P A
Nguyen, Q D
Article History
Received: 24 December 2014
Accepted: 10 June 2015
First Online: 31 July 2015
Competing interests
: QDN is a recipient of a Physician Scientist Award from Research to Prevent Blindness, New York, NY. PAC is the George S. and Dolores Doré Eccles Professor of Ophthalmology and Neuroscience. QDN is a consultant for Bausch and Lomb and Santen, and has research support from Genentech, MacuSight, Santen, L-Path, Ophthotech, and Regeneron, and has institutional consulting agreement with AbbVie, and honorarium from Bayer, XOMA, Heidelberg, and Quantel. QDN also chairs the Steering Committee for the RISE and RIDE Study, and is on the Steering Committee for the VISTA Study, and other studies sponsored by Genentech and Regeneron. DVD is a consultant for Genentech, Regeneron, Santen, and Allergan and she has received research support from Genentech and Regeneron, and honorarium from Heidelberg and Quantel. DVD also chairs the Steering Committee for the VISTA Study. PAC has institutional consulting agreements with Genentech and GlaxoSmithKline, is a consultant for Allergan, and formerly consulted for Amira, Potentia, and LPath, and served on the data and safety monitoring committee for a phase III trial sponsored by Regeneron, Inc., and has research support from Genentech, Alimera, and Molecular Partners for diabetic macular edema trials and GlaxoSmithKline, Genezyme, and Oxford BioMedica for neovascular AMD trials. These activities are being managed by the Conflict of Interest Committee of the Johns Hopkins University School of Medicine. LH is a stockholder in Covalent Medical LLC and a consultant to Regeneron Pharmaceuticals. DB is a consultant for Allergan, Alcon, Bausch and Lomb, Genentech, Regeneron, Allegro, Neurotech, Ohr, Quantel, Thrombogenics, Allergan, Alcon, Ampio, Thrombogenics, Allegro, Novartis, Roche, and Pfizer. DC is a consultant for Allergan, Alcon, Bausch & Lomb, and Regeneron. DMM is an advisory board member and consultant for Genentech, Regeneron, and Thrombogenics, and receives clinical research support from Genentech, Regeneron and Thrombogenics, Alcon, Allergan, GSK, Pfizer, Acucela, Lpath, Ophthotech, and Quark. The remaining authors declare no conflict of interest.